Business Wire

E4LIFE

Share
“e4life” is Present at Expomed Eurasia with its Innovative Device Able to Inactivate Flu and Covid Viruses With an Efficacy over 90%

Expomed Eurasia, the most important medical exhibition between Europe and Asia, is ready to house more than a hundred companies, to discover new technological trends and the most innovative products which are going to change deeply the health market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240419226980/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

e4life: e4ambient and e4you devices (Photo: Business Wire)

This is a perfect occasion for e4life to present its device based on the e4shield technology which is able to inactivate flu and Covid viruses present in the air. A technology, patented in Italy, that uses neither chemical agents nor filtering materials, but it is based on the transmission of electromagnetic waves able to inactivate the viral load in aerosol.

“This Exhibition represents an extraordinary opportunity to present our innovative technology (e4shield) in a dynamic and rapidly evolving region as Eurasia. In a climate of growing consciousness of the importance of health and of the diseases’ prevention, there is a growing need for smart and technologically advanced solutions that can guarantee safe environments for people. e4life, with its extremely innovative technology, represents the most effective answer to this need. The features of our devices are unique in the market and can enormously contribute in improving people health and wellbeing” explains Vincenzo Pompa, CEO of e4life.

e4life has been launched thanks to a joint venture between two global leaders: ELT Group, world leader for over 70 years in Electronic Defense systems, and Lendlease, specialized in major urban regeneration projects.

The e4shield technology, which is the core of e4life, was given birth during the Covid period thanks to the initiative of a researcher of the ELT Group who explored the use of electromagnetic fields to inactivate viruses. Based on research by a group of Taiwanese scientists published in the scientific journal Nature, he began to get his first results by testing different frequencies of electromagnetic waves at first on Covid-19 and later on other Coronaviruses.

The devices distributed by e4life guarantee an efficacy over 90% and their inactivation power is almost instantaneous. During their use it is not necessary to evacuate the rooms, because it is harmless to humans and animals. The electromagnetic impulses used are safe. This applies both to the environmental version of the device (e4ambient), which acts in an area of about 50 square meters, and to the wearable release (e4you), CE and SAR certified, which guarantees that the device can be worn for as long as wished without any risks for the health.

The technology utilized in e4life devices has been tested under rigorous and scientific analyses and had been validated by the Celio Military Hospital, by the independent Research Institute ViroStatics and by a recent range of tests developed by the Department of Biomedical and Clinical Sciences of the University of Milan (Italy). These last findings confirm what obtained in the previous tests: an extraordinary efficacy of 90%.

This technology and its efficacy against respiratory viruses had been reported by two recent issues on the periodical Viruses (June 2023) and on the European Society of Medicine (October 2023).

e4life technology is constantly evolving and can be adapted to an increasing number of viruses and, in a near future, to other micro-organisms too (e.g. bacteria). Thanks to the constantly evolving scientific research, these devices will be able to inactivate an ever growing number of different pathogens.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240419226980/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Samsung Bioepis Gains European Commission (EC) Approval for Denosumab Biosimilar (OBODENCE™, XBRYK™)16.2.2025 00:00:00 CET | Press release

OBODENCE™ and XBRYK™ approved by the European Commission (EC) for all indications referencing Prolia and Xgeva, respectivelyMarks Samsung Bioepis’ 10th and 11th product and first endocrinology treatment approved by the EC – adding to its growing portfolio of biosimilars Samsung Bioepis Co., Ltd. today announced that the European Commission (EC) has granted marketing authorization for OBODENCE™ (60mg pre-filled syringe) and XBRYK™ (120mg vial), denosumab biosimilars referencing Prolia and Xgeva – formerly referred to as SB16. OBODENCE, referencing Prolia, has been approved for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures, treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures, and treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. XBRYK, referencing Xgeva, has been approved for the prevention of skel

U.S. FDA Grants Full Approval of Deciphera’s ROMVIMZA™ (vimseltinib) for the Treatment of Symptomatic Tenosynovial Giant Cell Tumor (TGCT)15.2.2025 00:50:00 CET | Press release

In the MOTION Phase 3 study, ROMVIMZA met primary endpoint of improved objective response rate (ORR) compared to placebo and all key secondary endpoints with statistically significant and clinically meaningful improvements in quality-of-life measures, and demonstrated well-tolerated safety profile Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) announced that the U.S. Food and Drug Administration (FDA) has approved ROMVIMZA™ (vimseltinib), a kinase inhibitor, for adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause worsening functional limitation or severe morbidity. The FDA previously granted Fast Track designation and Priority Review for ROMVIMZA, which was developed by Deciphera Pharmaceuticals, Inc. (“Deciphera”), a wholly owned subsidiary of Ono. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214768549/en/ “

Venture Global, Inc. Announces Timing of Fourth Quarter and Full Year 2024 Earnings Release and Conference Call14.2.2025 19:17:00 CET | Press release

Venture Global, Inc. (“Venture Global”)(NYSE: VG) announced today that it plans to issue its earnings release with respect to fourth quarter and full year 2024 financial results before market open on Thursday, March 6, 2025. Venture Global will host a conference call for investors and analysts beginning at 9:00 am Eastern Time (ET) on March 6, 2025, to discuss fourth quarter and full year results and provide guidance for the 2025 fiscal year. A listen-only webcast of the call and accompanying slide presentation will be available at Venture Global’s Investor Relations website HERE. After the conclusion of the webcast, a replay will be made available on the Venture Global website. About Venture Global Venture Global is a long-term, low-cost provider of U.S. LNG sourced from resource rich North American natural gas basins. Venture Global’s business includes assets across the LNG supply chain including LNG production, natural gas transport, shipping and regasification. Venture Global’s fir

Asa Gudmundsdottir Wright Award Presented as Plans for New Icelandic Academy of Science & Innovation Announced14.2.2025 17:35:00 CET | Press release

Recognizing Contributions to Science and Innovation Iceland’s President, Halla Tomasdottir, presented the Asa Gudmundsdottir Wright Award at a ceremony at the presidential residence. This year’s recipients are G. Fertram Sigurjonsson, Founder and CEO of Kerecis, and Jon Atli Benediktsson, Rector of the University of Iceland. The award honors individuals who have made significant contributions to science and innovation in Iceland. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250214199674/en/ President Halla Tomasdottir and Kerecis Founder and CEO Fertram Sigurjonsson (Photo: Business Wire) During the ceremony, plans were also announced for the establishment of the Icelandic Academy of Science & Innovation, into which the award recipients will be inducted as members. The academy will provide a platform for collaboration between researchers, entrepreneurs, industry representatives, and academia. It will uphold the tradition o

Riskified To Report Fourth Quarter and Full-Year 2024 Financial Results on Wednesday, March 514.2.2025 17:33:00 CET | Press release

Riskified Ltd. (NYSE: RSKD), a leader in ecommerce fraud and risk intelligence, today announced it will release its fourth quarter and full-year 2024 financial results before the market opens on March 5, 2025. On that day management will host a conference call and webcast at 8:30 a.m. ET to discuss the company's business and financial results. Riskified Fourth Quarter and Full-Year 2024 Financial Results Conference Call When: Wednesday, March 5, 2025 Time: 8:30 a.m. ET Dial-in: To access the conference call via telephone, please register via this registration link and you will be provided with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. Webcast: A live and archived webcast of the conference call will be accessible from the “Events & Presentations” section of the Company’s Investor Relations website at https://ir.riskified.com/. About Riskified Riskified (NYSE:RSKD) empowers businesses to

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye